Page 1,456«..1020..1,4551,4561,4571,458..1,4701,480..»

Scientists Manipulate ‘Signaling’ Molecules to Control Cell Migration – Bioscience Technology

Posted: June 29, 2017 at 11:42 am

Johns Hopkins researchers report they have uncovered a mechanism in amoebae that rapidly changes the way cells migrate by resetting their sensitivity to the naturally occurring internal signaling events that drive such movement. The finding, described in a report published online March 28 in Nature Cell Biology, demonstrates that the migratory behavior of cells may be less hard-wired than previously thought, the researchers say, and advances the future possibility of finding ways to manipulate and control some deadly forms of cell migration, including cancer metastasis.

"In different tissues inside the body, cells adopt different ways to migrate, based on their genetic profile and environment," says Yuchuan Miao, a graduate student at the Johns Hopkins University School of Medicine and lead author of the study. "This gives them better efficiency to perform specific tasks." For example, white blood cells rhythmically extend small protrusions that allow them to squeeze through blood vessels, whereas skin cells glide, like moving fans, to close wounds.

On the other hand, Miao notes, uncontrolled cell migration contributes to diseases, including cancer and atherosclerosis, the two leading causes of death in the United States. The migration of tumor cells to distant sites in the body, or metastasis, is what kills most cancer patients, and defective white blood cell migration causes atherosclerosis and inflammatory diseases, such as arthritis, which affects 54 million Americans and costs more than $125 billion annually in medical expenditures and lost earnings.

Because cells migrate in different ways, many drugs already designed to prevent migration work only narrowly and are rarely more than mildly effective, fueling the search for new strategies to control migratory switches and treat migration-related diseases, according to senior author Peter Devreotes, Ph.D., a professor and director of the Department of Cell Biology at the Johns Hopkins University School of Medicines Institute for Basic Biomedical Research.

People have thought that cells are typed by the way they look and migrate; our work shows that we can change the cell's migrating mode within minutes, adds Devreotes.

For the new study, Devreotes and his team focused on how chemical signaling molecules activate the motility machinery to generate protrusions, cellular feet that are a first step in migration. To do this, they engineered a strain of Dictyostelium discoideum, an amoeba that can move itself around in a manner similar to white blood cells. The engineered amoebae responded to the chemical rapamycin by rapidly moving the enzyme Inp54p to the cell surface, where it disrupted the signaling network. The cells also contained fluorescent proteins, or markers, that lit up and showed researchers when and where signaling molecules were at work.

Experiments showed that the engineered cells changed their migration behavior within minutes of Inp54p recruitment. Some cells, which the researchers termed oscillators, first extended protrusions all around the cell margins and then suddenly pulled them back again, moving in short spurts before repeating the cycle. Fluorescent markers showed that these cycles corresponded to alternating periods of total activation and inactivation, in contrast to the small bursts of activity seen in normal cells.

Other cells began to glide as fans, with a broad zone of protrusions marked by persistent signaling activity.

Devreotes describes the signaling behavior at the cell surface as a series of waves of activated signaling molecules that switch on the cellular motility machinery as they spread. In their normal state, cells spontaneously initiated signaling events to form short-lived waves that made small protrusions.

In contrast, oscillators had faster signaling waves that reached the entire cell boundary to generate protrusions before dying out. Fans also showed expanded waves that continually activated the cell front without ever reaching the cell rear, resulting in wide, persistent protrusions.

The scientists say their experiments show that the cell movement changes they saw resulted from lowering the threshold level of signaling activity required to form a wave. That is, cells with a lower threshold are more likely to generate waves and, once initiated, the activation signals spread farther with each step.

Devreotes says the teams experimental results offer what appears to be the first direct evidence that waves of signaling molecules drive migratory behavior. Previously, his laboratory showed a link between signaling and migration, but had not specifically examined waves.

In further experiments, Devreotes and his team found that they could recruit different proteins to shift cell motility, suggesting, he says, that altering threshold is a general cell property that can change behaviorno matter how cells migrate. His team was also able to restore normal motility to fans and oscillators by blocking various signaling activities, suggesting new targets for drugs that could be designed to control migration.

Devreotes cautions that what happens in an amoeba may not have an exact counterpart in a human cell, but studies in his lab suggest that something like the wave-signaling mechanism they uncovered operates in human cells as well.

The bottom line, says Miao, is that we now know we can change signaling wave behavior to control the types of protrusions cells make. When cells have different protrusions, they have different migratory modes. When we come to understand the essential differences between cells migratory modes, we should have better ways to control them during disease conditions.

Follow this link:
Scientists Manipulate 'Signaling' Molecules to Control Cell Migration - Bioscience Technology

Posted in Cell Medicine | Comments Off on Scientists Manipulate ‘Signaling’ Molecules to Control Cell Migration – Bioscience Technology

Siberian scientists say stem cells can treat varicose veins – Russia Beyond the Headlines

Posted: June 29, 2017 at 11:42 am

Scientists at the Institute of Chemical Biology and Fundamental Medicine (ICBFM) based in Siberia have discovered that stem cells can restore blood flow in veins with clots.

Facebook

Pinterest

WhatsApp

"Quite a lot of pathologies regarding veins still remain unstudied." Source: Getty Images

To help treat varicose veins, scientists need to accelerate the growth of blood vessels, which would be a crucial development for cardiac medicine. A heart attack is caused by damaged arteries, and an ischemic stroke also often results from vascular damage.

"Quite a lot of pathologies regarding veins still remain unstudied," said Igor Mayborodin, a doctor of medical sciences at the stem cell laboratory at ICBFM. "Weve looked into blood flow restoration in situations when there are blood clots. Now were trying to use stem cells to stimulate the growth of veins and bypass the diseased area."

The discovery by Siberian scientists will make it possible to successfully treat diseases of the veins and resulting complications, for example, varicosis, phlebothrombosis (the formation of a blood clot in the vein that leads to its blockage), and even some types of trophic ulcers and cerebral strokes.

Researchers conducted a number of studies on rats, injecting them with stem cells taken from their relatives. The experiment showed that within a week small vessels had formed in the rodents, and in the third week the replacement of the introduced cells with the rodents' own cells began.

The new blood vessels remained in the body but stem cells that formed walls were gradually replaced by those of the rodents. Thus, scientists showed that stem cells can restore blood flow, bypassing damaged veins. Based on the results, a series of articles will be prepared.

Also, scientists witnessed unexpected side effects. "Some of the stem cells die, and then macrophages are attracted to the site, that is, 'ingester' cells capable of actively engulfing and digesting the remains of dead cells," Mayborodin said. "This is what helps a surgical wound be rid of damaged tissue quicker and heal. This is a good result."

The scientists are continuing their state-funded research, and they have obtained a patent for their work. For the time being, however, they cant check the results in clinical tests because Russian law restricts the use of stem cells on humans.

"Wed like to utilize the obtained data in regards to humans, but this is currently not possible," Mayborodin said. "For now were refining the results of the research on cell therapy and clarifying possible complications. But wed like to test our hypothesis at least on a severe case of varicosis in clinical conditions."

Continue reading here:
Siberian scientists say stem cells can treat varicose veins - Russia Beyond the Headlines

Posted in Cell Medicine | Comments Off on Siberian scientists say stem cells can treat varicose veins – Russia Beyond the Headlines

AML: Cellectis testing allogenic CAR-T cell therapy – European Biotechnology

Posted: June 29, 2017 at 11:41 am

Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.

The company said it enrolled the first patient with acute myeloid leukaemia (AML) to be treated with UCART123 at Weill at Cornell Medicine, New York Presbyterian Hospital. UCART123 is a TALEN-genome edited chimeric T cell receptor targeting the CD123/IL3R antigen on the surface of blasts and dendric cells, which is administered on allogeneic donor T cells. The team of Gail J. Roboz will investigate the safety and will collect first indications for efficacy of UCART123 in patients with AML. The Phase I trial is part of a strategic translational research alliance that was formed between Cellectis and Weill Cornell Medicine in 2015.

While Novartis AG and Kite Pharma are leading the CAR-T cell therapy development in AML, Cellectis hopes to overtake its competitors. It has the only approach that works with allogenic CAR-engineered T cells that could be centrally pre-manufactured in contrast to the autologous patient T cells. Those need to be isolated, engineered and expanded during the at least 14 day hospital stay of the patients to be treated making the procedure costly, lengthy and laborious. On the other hand, Cellectis therapy does not target the CD19 T cell antigen but CD123//IL3R giving the company another unique selling point.

Cellectis has used TALEN technology to block expression of the TCRa constant (TRAC) gene though blocking expression of the natural TCR. According to Andr Choulika, Cellectis CEO, TALEN technology shows less off-target effects compared to CRISPR/Cas9 genome editing. Following apheresis, donor T cells are engineered to express an anti-CD123 CAR (CD123 scFv-41BB-CD3z) and an RQR8 depletion ligand that confers susceptibility to rituximab. Theoretically, specifity of of UCART123 therapy might be higher in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) than in patients with AML as CD123 expression is 10fold higher in the precursors of plasmacytoid dendritic cells than in blast occurring in the course of AML.

Cellectis also announced two new entries to ists Board of Directors. Ex-Novartis pharma division head Rainer Boehm will lead commercialisation of Cellectis lead candidate. Ex Novartis Oncology President and Incyte Corp CEO Herv Hoppenot will lead clinical development.

Go here to read the rest:
AML: Cellectis testing allogenic CAR-T cell therapy - European Biotechnology

Posted in Cell Therapy | Comments Off on AML: Cellectis testing allogenic CAR-T cell therapy – European Biotechnology

New approach in T-cell therapy to treat cancer – Scientist Live

Posted: June 29, 2017 at 11:41 am

With numerous different entities and millions of people affected, cancer continues to be one of the most prevalent diseases around the world.

Scientists are working to find new treatment possibilities, and have been concentrating on the bodys own immune system for some time.

Because cancer emerges from the bodys own cells, it is usually difficult for the immune system to distinguish good cells from bad ones, explains Prof Dr Elfriede Nner, head of the Tissue Control of Immunocytes Research Group at the Helmholtz Zentrum Mnchen. But there are ways to support the immune system in recognizing and combating cancer cells.

Focus on T-cell therapy

One approach is the so-called adoptive T-cell therapy, which involves removing immune cells from the body and genetically arming them.

The cells are given new structures on the surface that accurately lead them to the cancer cells.

One limitation in this form of therapy is that the binding between the immune cell and the cancer cell is often somewhat weak.

Although this binding can be artificially strengthened, doing so also increases the risk of unwanted binding to healthy structures in the body, explains study leader Nner. She and her team were therefore searching for a different way to improve the defence provided by the immune cells.

Attack instead of sleep mode

In the current work, the researchers present a new surface molecule which comprises two halves.

On the outside, it preferentially binds to the PD-L1 molecule, which tumour cells often form in order to thwart the attacking immune cells.

On the inside of the T-cells, however, this binding does not activate a sleep mode (which the natural protein would do), and instead activates the T-cells killer programme, making it especially aggressive.

Experimental models showed that T-cells armed in this way proliferate more strongly in the tumours and destroyed more tumour cells.

The next step will be to confirm the findings in clinical studies.

If that step succeeds, the approach would enlarge the arsenal of T-cells suitable for adoptive T-cell therapy, Elfriede Nner states. This could not only make the treatment more effective but would allow it to be used in more patients in the framework of personalised medicine.

The work was the result of close cooperation with the team headed by Dr. Matthias Leisegang from the Institute of Immunology at the Charit Berlin Buch Campus and Prof Dr Dolores J Schendel, CEO and CSO at Medigene AG. The authors Ramona Schlenker, Luis Felipe Olguin Contreras, Anja Disovic and Julia Schnappinger attend the Helmholtz Graduate School Environmental Health, or HELENA for short.

Original Publication: Schlenker, R. et al. (2017): Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumour-infiltrating lymphocytes for adoptive cell therapy. Cancer Research, DOI: 10.1158/0008-5472.CAN-16-1922

The rest is here:
New approach in T-cell therapy to treat cancer - Scientist Live

Posted in Cell Therapy | Comments Off on New approach in T-cell therapy to treat cancer – Scientist Live

Is Sangamo Therapeutics Pointing Toward Success? – Seeking Alpha

Posted: June 29, 2017 at 11:41 am

Sangamo Therapeutics (SGMO) is a $650 million dollar market cap company focused on gene and cell therapies, including conducting the first-ever genome editing studies in clinical trials. The company uses gene therapy, genome editing, cell therapy, and gene regulation techniques to develop novel therapies. In gene therapy, attenuated Adeno-Associated Viral ((NYSE:AAV)) delivery systems are employed to carry functional gene copies to patients suffering from an ineffective or absent protein causing a disease state, such as in Hemophilia A (in collaboration with Pfizer (NYSE:PFE). The company is developing genome editing technologies for Hemophilia B and various lysosomal storage disorders, employing zinc finger nucleases (ZFN) to knock out harmful, defective, or unwanted proteins and also to insert helpful donor genes. The company is also utilizing gene editing and cell therapy techniques (T cell and stem cell) to treat HIV, and is partnering with Bioverativ (BIVV) to develop stem cell treatments for beta-thalassemia and sickle cell disease. Cell therapy can be used in conjunction with ZFN technology after harvesting afflicted cells, treating, testing for desired effects, cultured, then reinfused into the patient. Because ZFPs are the most common DNA binding motif in transcription factors of eukaryotic systems, gene repression or activation systems can be generated. SGMO is pursuing in central nervous system afflictions such as Huntington's Disease (in collaboration with Shire (SHPG)), by using specific gene repression of mutant disfunctional HTT gene but leaving functional gene products unchanged. Sangamo is attacking Alzheimer's and various tauopathies utilizing the same approaches. The company is also advancing non-therapeutic technologies with Sigma-Aldrich Corporation and Dow AgroScience.

Pfizer is a leading developer of AAV-based technologies. SGMO and Pfizer's collaboration in hemophilia A in May 2017 to develop AAV-based drug candidate gene therapy SB-525, one of Sangamo's four lead drug candidates, has received orphan drug status and fast track from FDA and EMA, and was perceived by the market as a big boost of confidence for Sangamo. The stock is up over 100% since the announcement. Pfizer made an initial payment of $70 million with up to $475 million in potential milestones, with $175 million potential for additional gene therapies if opted by Pfizer. Mikael Dolsten, president of worldwide research and development at Pfizer, stated, "We believe SB-525 has the potential to be a best-in-class therapy" that could provide stability to patients "with a single administration treatment." SGMO ZFN technology had recently been overshadowed in market sentiment by next-generation genome-editing technologies such as CRISPR prior to the announcement.

The company announced in the first quarter 2017 that it had received orphan drug designation (ODD, previously attained) and fast track designation from FDA for genome editing treatment SB-FIX for Hemophilia B. SGMO also progressed in lysosomal disorders by obtaining Rare Pediatric Disease Designation for in vivo genome editing treatment SB-318 for MPS I. In this disorder a deficiency in alpha-L iduronidase results in toxic buildup of glycosaminoglycans. According to the 2017 first quarterly report, "a sponsor who receives approval for a new drug application or biologics license application may be eligible to receive a voucher for a priority review of a subsequent marketing application for a different product. The voucher may be used by the sponsor or sold or transferred." SB-318 had also previously received ODD. The company also received ODD and Rare Pediatric Disease Designation for in vivo genome editing treatment SB-913 for MPS II (Hunter's disease). In this disorder, iduronate-2-sulfatase deficiency results in the buildup of glycosaminoglycans as well.

Sangamo's ZFN-mediated genome editing program for sickle cell disease and beta-thalassemia hemoglobinopathies transferred to Bioverativ in November of 2016, as part of a 2014 deal with Biogen. Bioverativ spun off from Biogen in early 2017 as a separate entity with specific experts to handle transformation of therapies for these rare diseases. Experts in related blood diseases hemophilia A and B medications will oversee sales and marketing of its lead products ELOCTATE and ALPROLIX respectively, as part of the responsibilities of the company.

Sangamo is using ZFN-mediated genome editing in the HIV space as well. Sangamo Therapeutics' approach inserts a naturally occurring human mutation which renders individuals largely resistant to HIV into T-cells and is monitoring patients in an open label phase 2 trial. Sangamo's SB-728-T HIV drug candidate targets the most common form of HIV. A Phase 1/2 clinical trial is also being conducted to evaluate safety and efficacy of its stem cell candidate, SB-728-HSPC, in HIV patients.

At the preclinical level, in vitro human culture and animal model data demonstrated significant reduction of tau mRNA and tau protein expression using ZFP transcription factor-mediated gene regulation technology. Results from the laboratory studies were presented at the 13th International Conference on Alzheimer's & Parkinson's Diseases.

Sangamo recently raised approximately $72 million in a public offering June 21, 2017, at $7.25 per share. An analyst at Jefferies was recently impressed by the company's presentation at a conference, and set a $17 per share price target on the SGMO shares. The company says it plans to use the funds to develop genomic therapy product candidates and potentially acquire complementary businesses, technologies, or licenses. Additionally the analyst said that this stock can serve as a financial investment hedge against the emerging gene-editing technology of CRISPR.

The gene editing and cell therapy spaces are definitely unproven to some extent and risky. There is also competitive risk in that this company is going up against some of the best regarded technologies in a tough field of gene and cell therapies that are possibly further advanced, including CRISPR. However, the risks are higher for Alzheimer's and HIV than for more straight-forward indications such as Hemophilia A. Pfizer's $70 million stamp of approval should reinforce that argument. Given the high quality partnerships for SGMO and relatively diverse pipeline, the reward to risk ratio should be adequate for a long position at these prices. The company is still in early to mid-stage trials, but a breakthrough in a rare or fatal indication could be an inflection point for the stock.

As of end Quarter one the company estimated $132 million in cash, taken with the recent offering of ~$70 million and estimated quarterly burn rate of ~$30 million leaves about $170 million in cash. This is a significant cash runway but given the immaturity of the clinical trial pipeline it is hard to predict if more dilution will be necessary in coming years. With only about $3 million in quarterly revenues trickling in its doubtful that the company can go without diluting if something were to go wrong. However, with its nice strategic partnerships and potential milestones from Pfizer, if things go well in the Hemophilia A project the company could near a cash neutral position within a couple of years.

Strong Bio regards this stock as a great watchlist stock, with intent to invest on significant pullbacks over time. Future clinical trial updates that indicate novel and robust responses could indicate FDA breakthrough therapy designation-worthy therapies. Of particular interest to Strong Bio are the projects of Alzheimers, HIV and cancer, as they have potential to show strong benefit in large markets. However, waiting too long might put investors in a "pay over the top" position as the more lead project Hemophilia A, B, and HIV projects progress. Strong Bio targets an entry in the $6.75 range.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more here:
Is Sangamo Therapeutics Pointing Toward Success? - Seeking Alpha

Posted in Cell Therapy | Comments Off on Is Sangamo Therapeutics Pointing Toward Success? – Seeking Alpha

Fighting Diabetes With Food – Fortune

Posted: June 29, 2017 at 11:40 am

In the summer of 2012, Sami Inkinen was 36, wealthy, and semiretired. Trulia, the online real estate company he cofounded and nurtured from a startup to a business with some 20 million users, had filed to go public, and he had decided to cease his operational role. The eight-year journey had been rewarding but exhausting. Inkinen planned to focus on angel investing.

That would leave plenty of time for his main hobby: triathlons. A champion who obsessively tracks his biometrics, Inkinen was a fitness freak even by Silicon Valley standards. He had less than 8% body fat.

But life is full of ironic twists, and he was hurtling toward a particularly sharp one. Soon after Trulia went public, Inkinen noticed something strange: His blood sugar levels were above normal and rising. He was prediabetic.

Inkinen skipped the doctor and began researching on his own. After discovering a decades-old paper that showed Type 2 diabetes can be prevented and sometimes reversed through lifestyle changes alone, he switched to a low-carbohydrate, high-fat diet. As his blood sugar levels dropped, his excitement spiked.

This spring he took his mission even further: Inkinen launched Virta Health , a 60-person startup backed by $37 million in funding. The service combines Inkinens passiona data-heavy appwith the same medical approach that he credits with reversing his prediabetes. Virta is one of a handful of companies attempting to attack the epidemicsome 28 million Americans suffer from Type 2 diabeteswithout relying on medications.

Researchers long believed Type 2 diabetes was not curable, but today the prevailing view is that it can be reversed by weight loss, says Dr. George King, the chief scientific officer at Joslin Diabetes Center and a professor at Harvard Medical School.

More: A New Innovation for Type 2 Diabetes

In that sense, Inkinen is an improbable advocate. He seemed like an unlikely candidate to be heading toward Type 2 diabetes in the first place. A native of Finland, Inkinen was always very active, but his seemingly healthy diet was packed with sugar (in the form of fruit smoothies) and carbs (five bowls of oatmeal a day). After diagnosing himself as prediabetic, he abruptly cut back on carbs and sugar. (Today hes an evangelist for a ketogenic diet, the food trend of the moment in Silicon Valley. It embraces high-fat foods and limits carbs to less than 50 grams a day, the equivalent of a cup of brown rice.)

Inkinen credits that diet for fueling an epic journey: He and his wife rowed from Monterey, Calif., to Hawaii to raise awareness of the dangers of sugar. During the 45 days it took to paddle across 2,700 miles of the Pacific, Zillow ( z ) agreed to acquire Trulia for $2.5 billion. Still a board member, Inkinen approved the sale via satellite phone.

Having sold the company and completed his physical quest, Inkinen was ready for a new mission. Im not a spiritual person, he says, but I knew I had to make this happen. After he met Dr. Stephen Phinney, the author of the paper that had convinced him that diet could solve his condition, a solution began to take shape in Inkinens mind.

Today Virtas service begins with an in-depth video session with a company doctor, who goes over each patients medical history and lifestyle to develop an eating strategy. Virta mails customers devices to record blood sugar, ketones (which indicate low insulin), and blood pressure. Patients enter data into the app, and a wireless scale automatically sends their weight to Virta. Each patient is then assigned a health coach, who monitors the data.

Users text their coaches daily via the app (some people prefer to call or use video chats). Advice gets granular. If a patient is planning to attend a birthday party, for example, her health coach could help develop an eating strategy beforehand.

Many patients are on medications when they begin the Virta program, and the goal is to slowly transition them off. Both meal recommendations and medications are constantly adjusted depending on what is, and isnt, having a positive effect on blood sugar, says Dr. Sarah Hallberg, the companys medical director.

Virta subscribes to a low-carb diet with moderate protein and fat, but its not doctrinaire. We accept any lifestyle and diet, says Inkinen. Instead of telling a person to swear off fast food, an often unrealistic option, health coaches recommend low-carb options on the menu. Physical activity is encouraged but not mandatory. You want someone to exercise when they come to you and say theyre ready, says Hallberg.

More: This Health Startup Plans to Challenge the Multibillion-Dollar Diet Industry

The service doesnt come cheap: It costs $400 a month (and isnt covered by insurance, though some employers health plans will reimburse for it). Virta has several thousand patients, according to Hallberg, served by about 20 health professionals.

The goal is to create a plan dramatic enough that it lowers blood sugar, but not so extreme that its unsustainable. In a clinical trial conducted in partnership with Indiana University Health, researchers found that 56% of the roughly 240 participants on the Virta platform lowered their blood sugar below diabetic levels by the end of the 10-week trial, and 87% no longer needed insulin.

Whether these results can be maintained is another question. The first couple of months of a diet are easy compared with an indefinite, fry-less future. Hallberg contends that the personalized support paired with the benefits of reduced medication and weight loss will keep people motivated despite the copious research establishing how hard most people find it to change their patterns.

Inkinen understands that as an endurance athlete he has more discipline (and capacity for suffering) than most people. His goal with Virta, as it was with Trulia, is to turn what was once a personal problem into a service that a large number of people can use. The stakes are higher this time around.

A version of this article appears in the July 1, 2017 issue of Fortune.

See more here:
Fighting Diabetes With Food - Fortune

Posted in Diabetes | Comments Off on Fighting Diabetes With Food – Fortune

Expanded diabetes center opens today – News – capecodtimes.com … – Cape Cod Times (subscription)

Posted: June 29, 2017 at 11:40 am

Cynthia McCormick @Cmccormickcct

WEST BARNSTABLE The YMCA Cape Cod is holding a grand opening of its newly renovated Weny Diabetes Resource Center at 5 p.m. today with an emphasis on nutrition counseling and classes for Cape Codders with diabetes and prediabetes.

Were trying to make this free and open to the public, said YMCA of Cape Cod CEO and President Stacie Peugh.

Individuals diagnosed with type 1 or 2 diabetes are entitled to five free visits with nutritionist Lauren Kunkler, Peugh said.

As part of its diabetes programming, the YMCA of Cape Cod also hosts prediabetes education and lifestyle coaching classes at the Mashpee-based Community Health Center of Cape Cod, Harbor Health Services in Hyannis, Duffy Health Center in Hyannis and the Falmouth Service Center, Peugh said.

The YMCA is planning to launch a support group for people with diabetes in collaboration with NAMI Cape Cod & the Islands, an advocacy group for people with mental illness, Peugh said.

There is actually a correlation between depression and diabetes, Peugh said during an interview in the newly renovated resource center, located by the front door of the YMCA.

With its blond wood shelving, soft blue-green walls and clear plastic furniture, the resource center is fairly small in size but was designed to appear bright and inviting, said Paula Drury of Brown, Lindquist Fenuccio & Raber Architects, the architect/designer for the project.

Located since 2008 at the back of the YMCA building where the front door used to be situated the new position is designed to attract the attention of the hundreds of people who enter the Y each day, Peugh said.

In addition to individual consulting, the diabetes center was designed to serve as a library and resource center for people with diabetes and their families, Drury said.

Websites relating to diabetes and health care have been built into two Apple desktop stations, and books and informational packets fill the resource centers book shelves.

The space and services offered are designed to help guide people past nutrition information overload and into useful, health-enhancing practices, Peugh said.

Diabetes is considered a metabolism disorder that affects the way the body uses food, according to information online from Cape Cod Healthcare.

The pancreas of diabetics either produces too little insulin, or the cells of the body do not respond to the insulin that is produced, according to the fact sheet.

The resulting glucose accumulation in the body can lead to multiple health issues including heart disease, kidney disease, stroke, nerve damage and blindness.

According to a public information platform called DataUSA, 8.6 percent of Barnstable County residents are living with diabetes. The percentage was based on data collected in 2013.

Todays open house will feature an appearance by Roger Ludwig, a trustee with the Weny Charitable Trust, and a discussion of the centers new partnership with NAMI, Peugh said.

Refreshments will be served. Peugh said the Weny Charitable Trust,which contributed $1 million to the expansion of the YMCA of Cape Cod 10 years ago, funded the relocation and renovation of the diabetes resource center with a gift of $100,000.

Follow Cynthia McCormick on Twitter: @CmccormickCCT.

Continued here:
Expanded diabetes center opens today - News - capecodtimes.com ... - Cape Cod Times (subscription)

Posted in Diabetes | Comments Off on Expanded diabetes center opens today – News – capecodtimes.com … – Cape Cod Times (subscription)

Diabetes management platform Glooko raises $35 million – TechCrunch

Posted: June 29, 2017 at 11:40 am

Glooko,a startup selling data management healthcare service on top of a device-agnostic platform to make it easier for doctors to remotely monitor patients,has pulled in $35 million Series C funding.It had previously raised $36 million in various rounds, bringing the total up to $71 million.

The startup was shy about how many were using the platform last time TechCrunch wrote about the company. But it was more forthcoming today, claiming to have helped more than 1 million patientsserved by 6,000+ providers so far.It will need to continue to rapidly expand to compete with some of the larger players in the space, like Dexcom and Medtronic.

Glooko plans to use the funding to help it get there by expanding itssales, marketing and development teams, as well asincreasing commercialization efforts in France, Germany, the U.K., Asia and the Middle East.

Toronto-based Georgian Partners led the round, along with other new investorsInsulet Corporation and Mayo Clinic. They join existing investors Canaan Partners, Social Capital, Medtronic and Samsung Next.

This additional funding will help us to further our mission: to improve the lives of people with diabetes, Glooko CEO Rick Altinger said. With this capital, we will accelerate our investments in clinical solutions that aim to increase medication adherence, provide personalized insights and prompts that drive behavior change for people with diabetes, and deliver clinical decision support to thousands of clinicians and coaches so they can better support people with diabetes in between office visits.

Read more:
Diabetes management platform Glooko raises $35 million - TechCrunch

Posted in Diabetes | Comments Off on Diabetes management platform Glooko raises $35 million – TechCrunch

If you really want to take control of your diabetes, follow these 4 tips – Star2.com

Posted: June 29, 2017 at 11:40 am

Lifestyle is a decisive factor in preventing or stabilising diabetes. From diet and exercise to stress management, here are a few lifestyle changes to consider.

Diabetics dont need to have to skip dessert, but they should definitely make wise food choices.

Pick products that have a naturally low glycemic index to prevent spikes in blood sugar.

Top fruits on that front are red berries (raspberries, strawberries, blackberries, blueberries), apples, pears, oranges, grapefruit, peaches and nectarines.

Note that cinnamon can help lower blood sugar levels.

It can be used to sweeten coffee or tea or sprinkled on yogurt or fromage frais.

Certain bakeries make cakes and cookies specifically for diabetics.

These sweet treats typically contain half the amount of sugar, notably by using natural sugar substitutes.

Still, they should only be eaten occasionally and always as part of a meal in order to limit the hyperglycemic effect.

Add berries and fruit to your deserts.

Most diabetics know that they should avoid pre-prepared supermarket dishes and ready meals.

These meals are often too high in fat and salt, and can be lacking in vitamins and minerals.

Cooking from scratch with quality produce remains the best option.

When it comes to grains, oats and barley are allowed.

These cereals fibres slow down the absorption of carbohydrates in the intestine and help control blood sugar levels and insulin requirements.

Walking for 10 minutes right after eating could be more effective for controlling blood sugar than walking at another time of day.

Do this after an evening meal, when blood sugar can drop by 22%, according to research from New Zealand.

Current recommendations from the World Health Organization (WHO) recommend at least the equivalent of 30 minutes of moderate-intensity physical activity per day, five times a week.

You can develop diabetes from too much stress and not enough sleep.

Unfortunately, it is possible to develop type-2 diabetes due to chronic stress from work or personal lives.

Permanent stress can contribute to increasing insulin resistance.

Thats why it is recommended to take regular exercise, learn relaxation techniques and organize break times on downtime in your day.

Keep an eye on shut-eye too (minimum seven hours sleep per night), as, according to several studies, this can help curb cravings for fatty or sugary foods, among other things. AFP Relaxnews

All comments are moderated. Your comment may not show up immediately. Please keep it clean and on topic. Offensive comments will not be published.

Continue reading here:
If you really want to take control of your diabetes, follow these 4 tips - Star2.com

Posted in Diabetes | Comments Off on If you really want to take control of your diabetes, follow these 4 tips – Star2.com

Scientists investigate link between air pollution and type 2 diabetes – Medical Xpress

Posted: June 29, 2017 at 11:40 am

June 29, 2017 Credit: CC0 Public Domain

An interdisciplinary team of scientists from the University of Leicester and other institutions has played a pivotal role in research investigating a possible link between air pollution and the rise in type 2 diabetes.

New research, published in the journal Environment International, examined data from 10,443 participants from diabetes screening studies in Leicestershire, UK.

The exposure to air pollution, the number of cases of type 2 diabetes and the impact of demographic and lifestyle factors were all considered.

The authors concluded that demographic factors largely explained the association between air pollution and type 2 diabetes.

The research team, supported by the NIHR, is comprised of University of Leicester experts from a wide variety of fields, including Earth Observation Science, the University's Diabetes Research Centre and the Department of Health Sciences and builds upon world-leading research in these areas.

Dr Gary O'Donovan, who led the research and is formerly of the University of Leicester and now at Loughborough University, said: "High air pollution and low physical activity are two of the leading causes of disease and premature death in middle and high-income countries.

"Like most cities in the UK, Leicester has only a handful of air quality monitors. The UN has estimated that two thirds of world's population will be living in cities by 2050 and our cities must become better, healthier places in which to live.

"Cities like Copenhagen in Denmark and Medelln in Colombia are doing a much better job of measuring air pollution and facilitating active transport than most cities in the UK."

Exposure to traffic related air pollutants is known to cause insulin resistance, a hallmark of the disease, and observational evidence has been applied to better understand a potential link.

Professor Roland Leigh, Technical Director of EarthSense and Director of Enterprise at the University of Leicester's Institute for Space and Earth Observation, and co-author of the study, said: "We know that air pollution is the world's largest environmental health risk affecting 92% of the population and associated with more than three million deaths per year, and evidence suggested it may contribute to the rise in type 2 diabetes.

"While original results suggested association between air pollution and associated particulates and type 2 diabetes, when the effects of lifestyle and demographic factors were considered, and given the limited size of the sample, evidence for direct association with air pollution was inconclusive.

"We will, however, continue to apply cutting-edge air quality research to unpick potentially connected long-term exposure factors," continued Professor Leigh. "As innovators in air quality monitoring, the University of Leicester and EarthSense has a fundamental contribution to make in the understanding of the complex issues of pollution exposure and health."

Diabetes is one of the leading causes of death in lower middle, upper middle and high income economies. The global prevalence of diabetes has nearly doubled, from 4.7% in 1980 to 8.5% in 2014, with the majority of cases being type 2. Experimental evidence exists to suggest exposure to nitrogen dioxide and associated particulate matter is related to inflammation and insulin resistance.

The CHAMPIONS Study into the association between air pollution and type 2 diabetes was conducted by representatives from the University of Leicester Diabetes Research Centre, University of Leicester Earth Observation Science Group, University of East Anglia Norwich Medical School and University of Leicester Department of Health Sciences.

EarthSense Systems is a joint venture between aerial mapping company Bluesky and the University of Leicester.

Explore further: New UK type 2 diabetes prevention programme shows 'promising' early results

More information: Gary O'Donovan et al, The association between air pollution and type 2 diabetes in a large cross-sectional study in Leicester: The CHAMPIONS Study, Environment International (2017). DOI: 10.1016/j.envint.2017.03.027

A programme aimed at preventing the development of Type 2 diabetes in people at high risk of the disease has achieved "promising" early results, a study has found.

People at high risk of developing type 2 diabetes can reduce their chances of getting the condition by more than 80 per cent by fully completing a new education programme, an NIHR-supported study has found.

Traffic noise, as well as air pollution, could affect heart health, according to new research.

Leading diabetes researchers believe smartphone craze Pokmon Go could be an "innovative solution" to rising obesity levels and chronic disease.

Exposure to air pollution at the place of residence increases the risk of developing insulin resistance as a pre-diabetic state of type 2 diabetes. Scientists of Helmholtz Zentrum Mnchen, in collaboration with colleagues ...

An interdisciplinary team of scientists from the University of Leicester and other institutions has played a pivotal role in research investigating a possible link between air pollution and the rise in type 2 diabetes.

A large, nationally representative survey in 2013 of adults in China finds that the estimated overall prevalence of diabetes was about 11 percent and that of prediabetes was nearly 36 percent, according to a study published ...

Some insulin is still produced in almost half of patients that have had type 1 diabetes for more than ten years. The study conducted by researchers at Uppsala University in Sweden has now been published online by the medical ...

Heart disease is a leading cause of death worldwide and exacerbated by type 2 diabetes, yet diabetes treatment regimens tend to focus primarily on blood sugar maintenance. This common approach to type 2 diabetes management ...

A team of researchers from Sweden, the U.S. and Switzerland has found that treating rat liver cells with a compound called sulforaphane, which is found in cruciferous vegetables, reduced production of glucose. In their paper ...

(HealthDay)For many people with diabetes, low blood sugar levels are a serious health risk, but researchers report that a new nasal powder quickly reverses the effects of this dangerous condition.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More:
Scientists investigate link between air pollution and type 2 diabetes - Medical Xpress

Posted in Diabetes | Comments Off on Scientists investigate link between air pollution and type 2 diabetes – Medical Xpress

Page 1,456«..1020..1,4551,4561,4571,458..1,4701,480..»